Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
PR NewswireFeb 21, 2023
BBT-401 meets safety endpoints achieved in previous clinical studies The drug candidate did not achieve an improved clinical response compared to the placebo study group 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Korea, Feb. 21, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology, announced the